NasdaqCM:ONCYBiotechs
Is It Time To Reassess Oncolytics Biotech (ONCY) After Recent Trial Progress News?
Wondering if Oncolytics Biotech at around US$0.95 is offering value or just extra risk? This article breaks down what that price tag could really mean for you.
The stock is roughly flat year to date with a 3.4% decline. It has returned 54.7% over the last year, which can raise questions about how much potential or risk might already be reflected in the price.
Recent coverage has focused on Oncolytics Biotech's progress as a clinical stage cancer therapy developer and the implications of its...